Startup profile · funding coverage
Orbital Therapeutics funding, valuation and investors
RNA medicines platform acquired by Bristol Myers Squibb for $1.5B in 2025.
Keep track of Orbital Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$270M · April 2023
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$270M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
acquired
acquired · Cambridge, MA
Overview
Orbital Therapeutics, founded in Cambridge, Massachusetts, built a platform for next-generation RNA-based medicines spanning vaccines, immunomodulation, and protein replacement — excluding siRNA. In April 2023 the company closed one of biotech's largest Series A rounds: $270M led by ARCH Venture Partners, with a16z Bio + Health among initial backers. Orbital integrated circular and linear RNA engineering, LNP delivery, and AI-driven design, and partnered with Beam Therapeutics on delivery tech. Its lead program OTX-201 is an investigational in vivo CAR T therapy targeting CD19 to deplete autoreactive B cells in autoimmune disease. Bristol Myers Squibb announced a definitive agreement in October 2025 to acquire Orbital for $1.5B cash, gaining the RNA platform and OTX-201.
Why Orbital Therapeutics is interesting
Orbital's $270M Series A and subsequent $1.5B BMS exit validate in vivo CAR T via RNA-LNP — reprogramming immune cells inside the body instead of ex vivo manufacturing.
Product & use cases
Orbital's integrated RNA platform combines engineering, delivery, data science, and automation to develop programmable RNA therapies. Lead asset OTX-201 uses circular RNA encoding a CD19 CAR delivered by targeted LNPs for in vivo immune reprogramming.
- In vivo CAR T for autoimmune B-cell depletion
- Next-gen RNA vaccines and immunomodulators
- Protein replacement therapies via engineered RNA delivery
Key facts
- Series A (2023): $270M led by ARCH — among largest biotech A rounds
- Lead program OTX-201: in vivo CD19 CAR T for autoimmune disease
- Acquired by BMS Oct 2025 for $1.5B cash
- Partnership with Beam Therapeutics on delivery
Funding history (newest first)
Investors in our directory
Funds linked from Orbital Therapeutics's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Orbital merged circular RNA, LNP delivery, and automated lab workflows — aiming for tissue reach and program breadth beyond first-gen mRNA players.
Orbital competed with large mRNA incumbents and cell-therapy players racing toward in vivo CAR T. BMS paid $1.5B primarily for OTX-201 and the RNA-LNP platform — a bet that body-as-bioreactor CAR T can beat ex vivo logistics in autoimmune disease.
-
Moderna incumbent
mRNA leader with manufacturing scale; less focused on in vivo cell reprogramming.
-
Beam Therapeutics adjacent
Partner on delivery; gene-editing focus vs Orbital's broader RNA platform.
-
Kyverna Therapeutics direct
Competing in vivo and ex vivo CAR T for autoimmune indications.
Notable stories
- CEO Giuseppe Ciaramella joined from Moderna's infectious-disease unit; Orbital split teams across Cambridge and San Francisco.
- BMS acquisition followed preclinical NHP data showing B-cell depletion across blood, spleen, and lymph nodes — first-in-human planned 1H 2026.
Industries
Related funding articles
Venture Capital Tracker pieces that cover Orbital Therapeutics's financing or category context.
FAQs about Orbital Therapeutics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.